$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
乳腺癌用瑞宁得治疗需要吃多长时间?
2025-10-19 11:44:20
Check Details
乳腺癌患者如何正确服用瑞宁得?
2025-10-19 11:44:20
Check Details
靶向药帕博西尼使乳腺癌患者有了新希望!
2025-10-19 11:44:20
Check Details
瑞宁得可有效改善绝经后乳腺癌患者的生存期
2025-10-19 11:44:20
Check Details
帕博西尼与来曲唑联合用于治疗绝经后ER阳性/HER2阴性进展期转移性乳腺癌
2025-10-19 11:44:20
Check Details
玻玛西林适用于激素受体阳性(HR+)和HER2阴性(HER2-)的乳腺癌的治疗
2025-10-19 11:44:20
Check Details
帕博西尼与氟维司群联合用于内分泌治疗后进展的ER阳性/HER2阴性乳腺癌
2025-10-19 11:44:20
Check Details
乳腺癌患者用玻玛西林可以延长多久的生存期?
2025-10-19 11:44:20
Check Details
全球首个批准上市的CDK4/6激酶抑制剂-帕博西尼
2025-10-19 11:44:20
Check Details
玻玛西林治疗单药治疗HR + / HER2-转移性乳腺癌的效果
2025-10-19 11:44:20
Check Details
抗癌药帕博西尼对乳腺癌患者有着较好的疗效
2025-10-19 11:44:20
Check Details
乳腺癌靶向药帕博西尼售价贵吗?在哪买的到?
2025-10-19 11:44:20
Check Details
1
2
...
1999
2000
2001
2002
2003
2004
2005
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
2
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
3
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
4
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
5
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
6
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
7
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
8
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
9
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
10
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
11
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
12
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity